Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pharvaris N.V. - Ordinary Shares (NQ:PHVS)

25.19 -0.65 (-2.52%)
Streaming Delayed Price Updated: 9:30 AM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pharvaris N.V. - Ordinary Shares

< Previous 1 2 3 Next >
News headline image
Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris To Present at the 18th German Allergy Congress
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris To Present at the 2023 HAEi Regional Conference EMEA
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces $70 Million Private Placement Financing
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Annual Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Present in Upcoming March Investor Conferences
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Present at SVB Securities Global Biopharma Conference
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Provides Regulatory, Clinical, and Corporate Updates
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Reports Third Quarter 2022 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Presents Data Supporting HAE Drug Development Strategy at the 2022 HAEi Global Leadership Workshop
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer
From Pharvaris N.V.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.